Improving Patient Adherence and Quality
of Life in CLL: Strategies for Anticipating, Recognizing, and
Managing Adverse Events in BTK Inhibitors and Combination Therapy
A continuing medical education
activity provided by NAMCP and AAMCN
Recent Advances in the Treatment and Management of Chronic
Lymphocytic Leukemia (CLL):
Expert Perspectives on the Evolving Role of BTK Inhibitors and
Combination Therapy is a three-part webinar series
This is Part 3 of the series focusing on improving adherence and
of life in chronic lymphocytic leukemia (CLL)
This activity is an archive from the webinar held March 19, 2021
This activity is valid from April 1, 2021 to April 1, 2023
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone
marrow that affects older adults. CLL is the most common type of
leukemia in adults. It affects B cell lymphocytes, which originate
in the bone marrow, develop in the lymph nodes, and normally fight
infection by producing antibodies. In 2021, it is expected that
there will be 20,720 new cases of CLL and about 3,930 deaths.
Fortunately for patients with CLL, several new treatments have
recently become available, including BTK inhibitors, giving
healthcare professionals many new options to improve patient
outcomes with these new treatments and strategies.
Upon completion of this
activity, participants will be able to:
Explore challenges to patient
adherence and quality of life in the management of CLL
Discuss strategies to continue the
implementation of BTK inhibitors and their combinations into the
treatment paradigm, especially as it relates to patient
adherence and quality of life
Compare and contrast the varying
adverse events that are associated with the use of BTK
inhibitors, and their combinations, in CLL
Formulate effective strategies for
ensuring the proper selection and use of BTK inhibitors in the
care of individual CLL patients and patient populations
||Matthew S. Davids, MD,
Associate Professor of Medicine, Harvard Medical School
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
has served on an advisory board for AbbVie Inc,
Ascentage Pharma, AstraZeneca Pharmaceuticals LP,
Genentech, a member of the Roche Group, Janssen Biotech
Inc, Lilly, Pharmacyclics LLC, an AbbVie Company, and TG
Therapeutics. He has served as a consultant AbbVie Inc,
Adaptive Biotechnologies Corporation, AstraZeneca
Pharmaceuticals LP, BeiGene, Genentech, a member of the
Roche Group, Janssen Biotech Inc, Lilly, MEI Pharma Inc,
Merk, Novartis, Pharmacyclics LLC, an AbbVie Company,
Verastem Inc, and Zentalis Pharmaceuticals. He has
received grants/research funding from AbbVie Inc,
Ascentage Pharma, AstraZeneca Pharmaceuticals LP,
Genentech, a member of the Roche Group, MEI Pharma Inc,
Novartis, Pharmacyclics LLC, an AbbVie Company, Surface
Oncology, TG Therapeutics Inc, and Verastem. His
presentation has been peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue